About Ibio (NYSEMKT:IBIO)
iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NYSEMKT:IBIO
- CUSIP: N/A
- Web: www.ibioinc.com/
- Market Cap: $34.7 million
- Outstanding Shares: 92,819,000
- 50 Day Moving Avg: $0.32
- 200 Day Moving Avg: $0.35
- 52 Week Range: $0.26 - $0.56
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.87
- P/E Growth: 0.0000
- Annual Revenue: $393,999.00
- Price / Sales: 88.06
- Book Value: $0.10 per share
- Price / Book: 3.74
- EBITDA: ($12,600,000.00)
- Net Margins: -2,945.58%
- Return on Equity: -161.21%
- Return on Assets: -45.28%
- Average Volume: 681,014 shs.
- Beta: 1.84
- Short Ratio: 4.59
Frequently Asked Questions for Ibio (NYSEMKT:IBIO)
What is Ibio's stock symbol?
Ibio trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "IBIO."
Who are some of Ibio's key competitors?
Some companies that are related to Ibio include Evoke Pharma (EVOK), Histogenics Corporation (HSGX), Juniper Pharmaceuticals (JNP), SCYNEXIS (SCYX), Amryt Pharma PLC (AMYT), Intellipharmaceutics International (IPCI), Pernix Therapeutics Holdings (PTX), Concordia International Corp. (CXRX), Apricus Biosciences (APRI), Cellectar Biosciences (CLRB), Venture Life Group PLC (VLG), Eyegate Pharmaceuticals (EYEG), Neuralstem (CUR), Galena Biopharma (GALE), Immune Pharmaceuticals (IMNP), Aegerion Pharmaceuticals (AEGR), Amryt Pharma PLC (FAST) and Avanir Pharmaceuticals (AVNR).
Who are Ibio's key executives?
Ibio's management team includes the folowing people:
- Robert B. Kay, Executive Chairman of the Board, Chief Executive Officer
- Robert L. Erwin, President
- James P. Mullaney, Chief Financial Officer
- Terence Ryan Ph.D., Chief Scientific Officer
- Glenn J. Chang CPA, Independent Director
- Arthur Y. Elliott Ph.D., Independent Director
- Seymour Flug, Independent Director
- James T. Hill, Independent Director
- John D. McKey Jr., Independent Director
How do I buy Ibio stock?
Shares of Ibio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ibio's stock price today?
MarketBeat Community Rating for Ibio (NYSEMKT IBIO)MarketBeat's community ratings are surveys of what our community members think about Ibio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Ibio stock can currently be purchased for approximately $0.37.
Consensus Ratings for Ibio (NYSEMKT:IBIO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Ibio (NYSEMKT:IBIO)
Analysts' Ratings History for Ibio (NYSEMKT:IBIO)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Ibio (NYSEMKT:IBIO)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Ibio (NYSEMKT:IBIO)
Current Year EPS Consensus Estimate: $-0.1500 EPS
Next Year EPS Consensus Estimate: $-0.2000 EPS
Dividend History for Ibio (NYSEMKT:IBIO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ibio (NYSEMKT:IBIO)Insider Trades by Quarter for Ibio (NYSEMKT:IBIO)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/7/2016||Eastern Capital Ltd||Major Shareholder||Buy||6,500,000||$0.62||$4,030,000.00|| |
|1/25/2016||Eastern Capital Ltd||major shareholder||Buy||3,500,000||$0.62||$2,170,000.00|| |
|9/17/2014||Carl Desantis||Major Shareholder||Sell||138,710||$0.67||$92,935.70|| |
|2/3/2014||Carl Desantis||Major Shareholder||Sell||28,828||$0.55||$15,855.40|| |
|1/31/2014||Carl Desantis||Major Shareholder||Sell||74,049||$0.56||$41,467.44|| |
|1/29/2014||Carl Desantis||Major Shareholder||Sell||128,708||$0.58||$74,650.64|| |
|8/13/2013||Carl Desantis||Major Shareholder||Sell||37,689||$0.50||$18,844.50|| |
|8/8/2013||Carl Desantis||Major Shareholder||Sell||324,395||$0.54||$175,173.30|| |
|8/6/2013||Carl Desantis||Major Shareholder||Sell||53,065||$0.50||$26,532.50|| |
|8/2/2013||Carl Desantis||Major Shareholder||Sell||99,945||$0.50||$49,972.50|| |
|7/30/2013||Carl Desantis||Major Shareholder||Sell||34,605||$0.51||$17,648.55|| |
|7/26/2013||Carl Desantis||Major Shareholder||Sell||27,255||$0.50||$13,627.50|| |
|7/23/2013||Carl Desantis||Major Shareholder||Sell||39,465||$0.51||$20,127.15|| |
|7/19/2013||Carl Desantis||Major Shareholder||Buy||1,732,679||$0.52||$900,993.08|| |
Headline Trends for Ibio (NYSEMKT:IBIO)
Latest Headlines for Ibio (NYSEMKT:IBIO)
Loading headlines, please wait.
Ibio (IBIO) Chart for Sunday, October, 22, 2017